Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05530421 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT05530421 · ClinicalTrials.gov record · last posted 2026-02-23

Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma

Study acronym: SELVEDge
StatusRecruiting
PhasePhase 2
Started2023-03-26
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
The purpose of this research is to determine whether the combination of selinexor, venetoclax, and dexamethasone therapy can increase anti-cancer effects in patients with translocation 11;14-positive (t(11;14)), relapsed/refractory myeloma (RRMM).

Amendment record 7 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 7 times since 2022-09-02; most recent amendment 2026-02-19. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2023-03-28
Status change Not Yet Recruiting→Recruitingv4
Trial Details
NCT Number NCT05530421
Lead Sponsor University of Miami
Collaborators: Karyopharm Therapeutics Inc
Conditions Relapsed and Refractory Multiple Myeloma
Enrollment 33 participants
Start Date 2023-03-26
Primary Completion 2028-03-26 (estimated)
Study Completion 2030-03-26 (estimated)
Updated on ClinicalTrials.gov 2026-02-23